The impact of addiction medications on treatment outcomes for persons with co‐occurring PTSD and opioid use disorders. (21st September 2015)

• Record Type: Journal Article
• Authors: Saunders, Elizabeth C.; McGovern, Mark P.; Lambert‐Harris, Chantal; Meier, Andrea; McLeman, Bethany; Xie, Haiyi
• Is Part Of: American journal on addictions. Volume 24:Number 8(2015)
• Page Start: 722
• Page End: 731
• Publication Date: 2015-09-21
• Subjects: medication‐assisted treatment -- opioid dependence -- co‐occurring disorders -- posttraumatic stress disorder -- integrated treatment; Substance abuse -- Periodicals; Substance abuse -- Treatment -- Periodicals; 616.86005
• DOI: 10.1111/ajad.12292
• Languages: English
• ISSNs: 1055-0496

Abstract

Abstract : Background and Objectives: Previous research has been inconclusive about whether adding psychosocial treatment to medication assisted treatment (MAT) improves outcomes for patients with co‐occurring psychiatric and opioid use disorders. This study evaluated the impact of MAT and psychosocial therapies on treatment outcomes for patients with co‐occurring opioid use disorders and PTSD. Methods: Patients meeting criteria for PTSD and substance use disorders were randomly assigned to one of three treatment conditions: Standard Care (SC) alone, Integrated Cognitive Behavioral Therapy (ICBT) plus SC, or Individual Addiction Counseling (IAC) plus SC. Substance use and psychiatric symptoms were assessed at baseline and 6 months. Only patients with opioid use disorders were included in the present analyses ( n = 126). Two‐way ANOVAS and logistic regression analyses were used to examine associations between treatment conditions and MAT, for substance use and psychiatric outcomes. Results: MAT patients receiving ICBT had significantly decreased odds of a positive urine drug screen, compared to non‐MAT patients receiving SC alone (OR = .07, 95% CI = .01, .81, p = .03). For PTSD symptoms, a significant MAT by psychosocial treatment condition interaction demonstrated that MAT patients had comparable declines in PTSD symptoms regardless of psychosocial treatment type (F(2, 88) = 4.74, p = .011). Non‐MAT patients in ICBT had significantly larger reductions in PTSD. Conclusions and Scientific Significance: For patients with co‐occurring opioid use disorders and PTSD, MAT plus ICBT is associated with more significant improvement in substance use. For non‐MAT patients, ICBT is most beneficial for PTSD symptoms. (Am J Addict 2015;XX:1–10)